FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Sanofi Pasteur | Leukocare

Sanofi taps Leukocare for vaccine stabilization

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


Sanofi Pasteur says it will examine Leukocare's Stabilizing and Protecting Solutions technology to see whether the platform could help the vaccine developer improve the shelf-life of its vaccines, according to a report in Genetic Engineering News. Financial details of the deal were not disclosed.

Germany-based Leukocare's technology helps stabilize proteins during storage in dehydrated conditions and protects proteins to maintain biological activity during sterilization by gamma-, beta-radiation or ethylene oxide, according to the company's website. Improving the stabilization of vaccines make them safer and more effective. Sanofi didn't say which of its vaccines it would target using Leukocare's technology.

- here's the report

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Sanofi Pasteur   Leukocare